Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan

Abstract Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and osteoporosis is the major comorbidity associated with poor prognosis in COPD. However, the effect of inhaled corticosteroids (ICS) on bone mineral density among COPD remains uncertain. There is the urgen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kai-Lin Chiu, Chun-Chen Lee, Chung-Yu Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/96c1eb26aa104ed794ca41c187d12ebd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96c1eb26aa104ed794ca41c187d12ebd
record_format	dspace
spelling	oai:doaj.org-article:96c1eb26aa104ed794ca41c187d12ebd2021-12-02T14:01:23ZEvaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan10.1038/s41598-020-80815-y2045-2322https://doaj.org/article/96c1eb26aa104ed794ca41c187d12ebd2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80815-yhttps://doaj.org/toc/2045-2322Abstract Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and osteoporosis is the major comorbidity associated with poor prognosis in COPD. However, the effect of inhaled corticosteroids (ICS) on bone mineral density among COPD remains uncertain. There is the urgent need to examine whether the long-term ICS use may increase the risk of osteoporosis. In this nested case–control study retrieved from the Taiwan National Health Insurance Research Database from 2002 to 2017, the study aimed to investigate risk of osteoporosis associated with ICS, focusing on the dosage and duration of ICS therapy. Cases with osteoporosis or osteoporotic fractures claims were defined and matched to 3 randomly selected controls. Conditional logistic regressions were used to estimate odds ratios of osteoporosis from ICS treatment measured in 3 years before the index date. This population-based study included 891,395 patients with COPD, where after matching had 58,048 case groups and 174,144 matched control groups. After adjusting for potential confounders, ICS use in COPD was associated with a 1.053-fold (95% confidence interval 1.020–1.087) increased osteoporosis risk, where 7892 (13.59%) ICS use in case and 22,580 (12.97%) in control. New ICS use in COPD patients is associated with increased osteoporosis risk, regardless of exposure period.Kai-Lin ChiuChun-Chen LeeChung-Yu ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kai-Lin Chiu Chun-Chen Lee Chung-Yu Chen Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
description	Abstract Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and osteoporosis is the major comorbidity associated with poor prognosis in COPD. However, the effect of inhaled corticosteroids (ICS) on bone mineral density among COPD remains uncertain. There is the urgent need to examine whether the long-term ICS use may increase the risk of osteoporosis. In this nested case–control study retrieved from the Taiwan National Health Insurance Research Database from 2002 to 2017, the study aimed to investigate risk of osteoporosis associated with ICS, focusing on the dosage and duration of ICS therapy. Cases with osteoporosis or osteoporotic fractures claims were defined and matched to 3 randomly selected controls. Conditional logistic regressions were used to estimate odds ratios of osteoporosis from ICS treatment measured in 3 years before the index date. This population-based study included 891,395 patients with COPD, where after matching had 58,048 case groups and 174,144 matched control groups. After adjusting for potential confounders, ICS use in COPD was associated with a 1.053-fold (95% confidence interval 1.020–1.087) increased osteoporosis risk, where 7892 (13.59%) ICS use in case and 22,580 (12.97%) in control. New ICS use in COPD patients is associated with increased osteoporosis risk, regardless of exposure period.
format	article
author	Kai-Lin Chiu Chun-Chen Lee Chung-Yu Chen
author_facet	Kai-Lin Chiu Chun-Chen Lee Chung-Yu Chen
author_sort	Kai-Lin Chiu
title	Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
title_short	Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
title_full	Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
title_fullStr	Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
title_full_unstemmed	Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
title_sort	evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in taiwan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/96c1eb26aa104ed794ca41c187d12ebd
work_keys_str_mv	AT kailinchiu evaluatingtheassociationofosteoporosiswithinhaledcorticosteroiduseinchronicobstructivepulmonarydiseaseintaiwan AT chunchenlee evaluatingtheassociationofosteoporosiswithinhaledcorticosteroiduseinchronicobstructivepulmonarydiseaseintaiwan AT chungyuchen evaluatingtheassociationofosteoporosiswithinhaledcorticosteroiduseinchronicobstructivepulmonarydiseaseintaiwan
_version_	1718392157367173120

Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan

Ejemplares similares